biotech Archives - Vista Partners LLC | HomeVista Partners LLC

Acquired Taste: Why Big Pharma Can’t Stop Snacking on Venture‑Backed Biotechs -( $IBB $MRK $OTSKY $NVS $TERN $XBI )

by John F. Heerdink, Jr. April 2, 2026 232Views 0Likes

Big Pharma spent the week shopping again, snapping up a fresh crop of biotech and pharmaceutical names in deals that underscore one message: pipelines are the new gold, and the majors are still happily paying spot prices. From autoimmune bets to allergy…

Eupraxia’s EP-104 Is Quietly Auditioning for a Starring Role In Eosinophilic Esophagitis -( $EPRX $SNY $TAK $IBB $XBI )

by John F. Heerdink, Jr. March 25, 2026 349Views 0Likes

Yes indeed, Eupraxia Pharmaceutical's (NASDAQ: EPRX) EP-104 is quietly auditioning for a starring role in eosinophilic esophagitis—and for once, the gastroenterologist, the allergist, and the payer might actually clap at the same time. A Chronic Disease Finally Meets a Long-Term Plan Eosinophilic…

From Lab Bench to Stockpile Shelf: GeoVax’s GEO-MVA Aims for the Big Leagues -( $GOVX $IBB $XBI )

by John F. Heerdink, Jr. March 25, 2026 191Views 0Likes

GeoVax’s (GOVX) latest update on its GEO-MVA program reads less like a small-cap press release and more like a biotech coming-of-age story, with Phase 3 now on the horizon and global health agencies finally circling the dance floor. For investors, the mpox/smallpox…

Merck’s Nearly $6 Billion Terns Buyout Deal Signals Big Pharma’s Next Act in Cancer—and Obesity? -( $MRK $TERN $LLY $NVS $IBB $XBI )

by John F. Heerdink, Jr. March 25, 2026 431Views 0Likes

Merck (MRK) is preparing to spend nearly $6 billion in cash to acquire Terns Pharmaceuticals (TERN), a move that reads like a carefully scripted sequel to its Keytruda blockbuster rather than an impulsive spin-off. The price represents a premium to Terns’ roughly…

Is NAYA Therapeutics the Next Radiopharma Takeout? The Pipeline, the Board, and the Buzz – ( $AZN $BMY $IBB $LLY $NVS $XBI )

by John F. Heerdink, Jr. March 18, 2026 274Views 0Likes

NAYA Therapeutics (https://www.nayatx.com) is quietly trying to make “next‑gen radiopharma” sound less like sci‑fi and more like standard operating procedure—and its new board lineup reads like a who’s who of oncology, nuclear medicine, and biotech capital markets. A New Board for a…

Servier’s $2.5 Billion Bet on Rare Oncology: A Strategic Day One Biopharmaceuticals Play With a Pediatric Pulse -( $DAWN $XBI $IBB )

by John F. Heerdink, Jr. March 6, 2026 907Views 0Likes

French pharmaceutical group Servier has quietly become one of the most methodical players in oncology—and its latest move underscores that reputation. The company announced a definitive agreement to acquire Day One Biopharmaceuticals (Nasdaq: DAWN) for $21.50 per share in cash, valuing the…

Ivonescimab vs Keytruda: The High‑Stakes HARMONi‑3 Interim That Could Flip the Script for Summit Therapeutics -( $MRK $SMMT $IBB $XBI )

by John F. Heerdink, Jr. February 24, 2026 301Views 0Likes

Summit Therapeutics’ (SMMT) latest tweak to its clinical playbook has turned what was already one of biotech’s higher‑stakes stories into something closer to appointment viewing for Wall Street. A Phase 3 Trial Adds a Plot Twist Summit now plans an interim progression‑free…

Eupraxia’s Latest Raise: A Diffusphere-Fueled War Chest Aims at GI Disease -( $EPRX $IBB $XBI $SNY)

by John F. Heerdink, Jr. February 21, 2026 223Views 0Likes

In a market that has grown wary of “story stocks,” Eupraxia Pharmaceuticals (NASDAQ: EPRX) just delivered something refreshingly old-fashioned: a fully closed, upsized equity offering that actually funds a clinical plan rather than a marketing slogan. The clinical‑stage biotech, which trades on…

GeoVax Tries on Its 2026 “Breakout Year” Jacket — And It Might Just Fit -( $GOVX $IBB $XBI )

by John F. Heerdink, Jr. February 17, 2026 430Views 0Likes

GeoVax Labs (NASDAQ: GOVX) is stepping into 2026 talking like an inflection‑year story—and, unusually for biotech, it has the clinical, regulatory and manufacturing pieces to at least justify the wardrobe change. While capital remains tight, the company is pairing late‑stage Mpox vaccine…

Eupraxia Pharmaceuticals: Injecting New Life Into EoE — One Microsphere at a Time -( $EPRX $SNY $XBI )

by John F. Heerdink, Jr. February 9, 2026 365Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX) may still wear the “clinical-stage” name tag, but its stock has been behaving like it already found a seat at the grown‑ups’ table on Wall Street. Over the past year, shares have climbed roughly 160%, far outpacing the…

Tag: biotech

Acquired Taste: Why Big Pharma Can’t Stop Snacking on Venture‑Backed Biotechs -( $IBB $MRK $OTSKY $NVS $TERN $XBI )

Eupraxia’s EP-104 Is Quietly Auditioning for a Starring Role In Eosinophilic Esophagitis -( $EPRX $SNY $TAK $IBB $XBI )

From Lab Bench to Stockpile Shelf: GeoVax’s GEO-MVA Aims for the Big Leagues -( $GOVX $IBB $XBI )

Merck’s Nearly $6 Billion Terns Buyout Deal Signals Big Pharma’s Next Act in Cancer—and Obesity? -( $MRK $TERN $LLY $NVS $IBB $XBI )

Is NAYA Therapeutics the Next Radiopharma Takeout? The Pipeline, the Board, and the Buzz – ( $AZN $BMY $IBB $LLY $NVS $XBI )

Servier’s $2.5 Billion Bet on Rare Oncology: A Strategic Day One Biopharmaceuticals Play With a Pediatric Pulse -( $DAWN $XBI $IBB )

Ivonescimab vs Keytruda: The High‑Stakes HARMONi‑3 Interim That Could Flip the Script for Summit Therapeutics -( $MRK $SMMT $IBB $XBI )

Eupraxia’s Latest Raise: A Diffusphere-Fueled War Chest Aims at GI Disease -( $EPRX $IBB $XBI $SNY)

GeoVax Tries on Its 2026 “Breakout Year” Jacket — And It Might Just Fit -( $GOVX $IBB $XBI )

Eupraxia Pharmaceuticals: Injecting New Life Into EoE — One Microsphere at a Time -( $EPRX $SNY $XBI )

Your Guide To Staying Informed In The Markets